Adalimumab biosimilar - Momenta Pharmaceuticals

Drug Profile

Adalimumab biosimilar - Momenta Pharmaceuticals

Alternative Names: BAX 2923; M 923

Latest Information Update: 02 Dec 2016

Price : $50

At a glance

  • Originator Momenta Pharmaceuticals
  • Developer Momenta Pharmaceuticals; Shire
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics
  • Mechanism of Action Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Plaque psoriasis; Rheumatoid arthritis
  • Phase I Autoimmune disorders; Inflammation

Most Recent Events

  • 29 Nov 2016 Efficacy and adverse events data from a phase III trial in Plaque psoriasis released by Momenta
  • 27 Sep 2016 Momenta Thearapeutics terminates its collaboration agreement with Shire for adalimumab biosimilar
  • 01 Jul 2016 Baxalta US completes a phase I clinical trial in Inflammation and Autoimmune disorders (In volunteers) in USA and United Kingdom (SC) (NCT02675023)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top